Medtronic has recalled certain implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators due to a defect in the manufacturing process that may prevent them from delivering the electrical shock needed to pace a heartbeat or revive a patient in cardiac arrest, the Food and Drug Administration announced yesterday. In an urgent notice to affected customers, the company said to consider replacing implanted devices affected by the recall. Health care professionals may report adverse reactions or quality problems using the devices to FDA’s MedWatch program.
 

Related News Articles

Headline
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…
Headline
The latest revisions to the Centers for Medicare & Medicaid Services’ Quality Assurance and Performance Improvement program underscore the integral role of…
Headline
The Centers for Medicare & Medicaid Services yesterday released updated interpretive guidance for surveyors assessing whether a hospital’s Quality…
Headline
The Food and Drug Administration today finalized a 2019 proposed rule updating requirements under the Mammography Quality Standards Act of 1992, which…
Headline
The Centers for Medicare & Medicaid Services Friday granted certain quality reporting exceptions to Texas acute-care hospitals, ambulatory surgical…
Headline
The blanket data reporting exceptions and extensions implemented in March across Medicare quality reporting and value-based payment programs for hospitals…